<DOC>
	<DOCNO>NCT01745757</DOCNO>
	<brief_summary>Bevacizumab plus chemotherapy improve response rate prolong PFS use first- second-line therapy advance breast cancer . However , bevacizumab improve OS individual study currently report . In Europe , EMEA maintain indication associate weekly paclitaxel first line metastatic breast cancer recently capecitabine base RIBBON 1 trial 's result . The identification patient subset receive clinical benefit would enable specific treatment administration bevacizumab allow patient unlikely benefit opportunity seek treatment modality . Unfortunately , despite effort identify patient subset differential benefit bevacizumab , validate biomarkers define . The Avastin cohort unique opportunity investigate various biological imaging parameter could relate clinical benefit combination bevacizumab weekly paclitaxel first line MBC homogeneously treat population French cancer center . This trial gather expertise several translational research platform different cancer center UNICANCER consortium .</brief_summary>
	<brief_title>Cohort Study Prospective Validation Predictive Factors Biological Imaging Response Bevacizumab Paclitaxel Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Male female age ( e ) 18 . Histologically confirm breast adenocarcinoma , metastatic ( measurable unmeasurable lesion ) , HER2 negative ( last tumor tissue analyze ) , Patient receive firstline chemotherapy paclitaxel bevacizumab weekly manner recommend EMEA . Hormone receptor status know ECOG performance status ≤ 2 . Life expectancy ≥ 12 week . Women childbearing age ( except amenorrhea least 24 month ) must negative pregnancy test serum within 28 day start treatment . In absence serum test , urine pregnancy test ( within 7 day first dose bevacizumab ) require . Informed consent form duly sign dated patient Prior chemotherapy metastatic disease ; Concomitant hormone therapy The patient must undergo radiation therapy treatment metastatic disease ( except case analgesic radiotherapy bone pain due metastasis ) . Pregnant nursing woman woman childbearing age ( except amenorrhea least 24 month ) use effective nonhormonal contraceptive method ( intrauterine device , barrier method associate use spermicidal gel surgical castration ) duration study 6 month paclitaxel administration / bevacizumab . Man accept use effective contraception study period 6 month paclitaxel administration / bevacizumab . Known hypersensitivity paclitaxel / bevacizumab excipients . Patient unable undergo medical test geographical , social psychological reason . Patient deprive liberty place authority tutor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>